NCT05417386 2025-11-18
FOLFIRINOX + NIS793 in Pancreatic Cancer
Massachusetts General Hospital
Phase 1 Terminated
Clinical Trials
16 trialsNCT04141995 2025-08-07
FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
University of Nebraska
Phase 2 Terminated
NCT03822936 2025-02-13
PIOPPO
CNAO National Center of Oncological Hadrontherapy
Phase 2 Terminated
NCT05546411 2024-12-17
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01897454 2023-12-05
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
Albert Einstein College of Medicine
Phase 2 Terminated
NCT03099265 2022-10-27
Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
Yale University
Phase 2 Terminated
NCT03600623 2020-08-18
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
University of Alabama at Birmingham
Phase EARLY_PHASE1 Terminated
NCT01836432 2020-05-28
PILLAR
Lumos Pharma
Phase 3 Terminated
NCT02405585 2020-05-28
Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
Lumos Pharma
Phase 2 Terminated
NCT01760252 2019-03-15
Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol
Beth Israel Medical Center
Phase 2 Terminated
NCT00276744 2018-10-24
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT02345460 2018-07-13
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT02331251 2018-07-02
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Western Regional Medical Center
Phase 1/2 Terminated
NCT02423954 2018-07-02
NivoPlus
Western Regional Medical Center
Phase 1/2 Terminated
NCT01688336 2017-10-06
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT01042028 2015-10-20
A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer
Odense University Hospital
Phase 1/2 Terminated